# Sermorelin References: The Cited Research Record

> Sermorelin references — the full cited research record behind this site, with DOIs, PubMed links, and trial identifiers for every quantitative claim.

The peer-reviewed and regulatory sources behind every quantitative claim on this site, with DOIs and PubMed links.

## How to read this list

Each numbered entry below corresponds to the inline markers used across the site. Where a claim reports a dose, a percentage, a duration, or a half-life, it maps to one of these sources. Several adult body-composition and cognition figures derive from the stabilized GHRH analog tesamorelin and are attributed as such in the text; the regulatory and prescribing history is sourced to the editorial and policy record.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. (SMART trial, NCT00257712.) https://pubmed.ncbi.nlm.nih.gov/22869065/
[7] Massoud AF, et al. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin. J Clin Endocrinol Metab. 1991;72(2):492-499. https://pubmed.ncbi.nlm.nih.gov/1671389/
[8] Lewinski A, et al. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It. Front Endocrinol (Lausanne). 2021;12:636403. https://pubmed.ncbi.nlm.nih.gov/33776931/
[9] Tauber MT, Pienkowski C, Pigeon P, et al. Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 in children with GH deficiency. Acta Paediatr Suppl. 1993;388:28-30; discussion 31. https://pubmed.ncbi.nlm.nih.gov/8329829/
[10] Bowers CY, Granda-Ayala R. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine. 2001;14:79-86. https://pubmed.ncbi.nlm.nih.gov/11322505/
[11] Sáez JM. Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer's disease treatment. Endocr Metab Immune Disord Drug Targets. 2012;12:274-86. https://pubmed.ncbi.nlm.nih.gov/22524398/
[12] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/
[13] Cai R, Schally AV, et al. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39934495/
[14] Schally AV, Cai R, et al. The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39592529/
[15] Gahete MD, et al. Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39579280/

---

The sermorelin record charted like an expedition — the GHRH(1-29) signal followed from pituitary to IGF-1, each figure carried back to its study, the body-composition data marked as tesamorelin where it belongs, and the stretch where the adult anti-aging evidence runs out left openly unmapped; no clinic behind the compass and nothing here prescribed, dispensed, or sold.